

- **Full Name:** Ning Li
- **Current Position & Affiliation:** Associate Professor  
Department of Gynecologic Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
- **Country:** China

---

**Educational Background:**

M.D.	North China Coal Medical College, Tangshan, China	Sept, 1993 – Jul, 1998
M.S.	Gynecologic Oncology Peking Union Medical College, Beijing, China	Sept, 2000 – Jul, 2003
Ph.D.	Gynecologic Oncology Peking Union Medical College, Beijing, China	Sept, 2005 – Jul, 2008
Visitor	Memorial Sloan- Kettering Cancer Center	Jan, 2011 – Mar, 2011
Visitor	Columbia University, New York-Presbyterian Hospital	Mar, 2011 – Apr, 2011

**Professional Experience:**

Intern	Medical School of Yamagata University, Yamagata, Japan	Sept, 1997–Jul, 1998
Resident	Department of Obstetrics and Gynecology, North China Coal Medical College Affiliated Hospital, Tangshan, China.	Aug, 1998 –Aug, 2000
Attending Physician	Department of Obstetrics and Gynecology, North China Coal Medical College Affiliated Hospital, Tangshan, China	Aug, 2003 – Aug, 2005
Attending Physician	Department of Gynecologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, National Cancer Center, Beijing, China	Aug, 2008 – Jul, 2015
Associate Professor	Department of Gynecologic Oncology, Present Cancer Hospital, Chinese Academy of Medical Sciences, National Cancer Center, Beijing, China	Aug, 2015 –

**Professional Organizations:**

- Member of Gynecologic Oncologist Committee, Chinese Society of Clinical Oncology

**• Main Scientific Publications:**

1. **Li N**, Zhang Y, Wang J, et al. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. *Journal of Clinical Oncology*, 2022, <https://doi.org/10.1200/JCO.21.01511>
2. TiantianWang, Jie Tang, Hongying Yang, Rutie Yin, Jingru Zhang, Qi Zhou, Ziling Liu, Lanqin Cao, Li Li, Yi Huang, Kui Jiang, WeiWang, Fenglin She, Ni Guan, Zhiguo Hou, **Ning Li#**, LingyingWu#. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer The APPROVE Randomized Clinical Trial. *JAMA ONCOL*. DOI:10.1001/JAMAONCOL.2022.2253
3. **Ning Li**, Hualei Bu, Jihong Liu, etc. An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline *BRCA1/2* mutation and platinum-sensitive recurrent ovarian cancer. *Clinical Cancer Research*. 2021, doi: 10.1158/1078-0432.Clinical Cancer Research -20-3546
4. Leilei Liang, Chengcheng Li, Yuchen Liao, Guoqiang Wang, Jiayue Xu, Yifan Li, Guangwen Yuan, Yangchun Sun, Rong Zhang, Xiaoguang Li, Yu Zhang, Weiqi Nian, Jing Zhao, Yuzi Zhang, Xin Zhu, Xiaofang Wen, Shangli Cai, **Ning Li\***, Lingying Wu\*. Plasma cfDNA methylation markers for the early detection and prognosis of ovarian cancer. *eBioMedicine*. 2022;83:104222 Published online <https://doi.org/10.1016/j.ebiom.2022.104222>
5. Jing Yu, Ting-Ting Liu, Lei-Lei Liang, Jing Liu, Hong-Qing Cai, Jia Zeng, Tian-Tian Wang, Jian Li, Lin Xiu, **Ning Li\*** and Ling-Ying Wu\*. Identification and validation of a novel glycolysis-related gene signature for predicting the prognosis in ovarian cancer. *Cancer Cell International* (2021) 21:353 <https://doi.org/10.1186/s12935-021-02045-0>